Overview

LGG Supplementation in Patients With AUD and ALD

Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH
Phase:
Phase 2
Details
Lead Sponsor:
University of Louisville
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)